Document is current
Any future updates will be listed below
-
Authors
Müller, Anne https://orcid.org/0000-0002-2456-2492
Hebben, Fabian https://orcid.org/0009-0003-6401-3433
Dillen, Kim
Dunkl, Veronika
Goereci, Yasemin
Voltz, Raymond
Löcherbach, Peter
Warnke, Clemens https://orcid.org/0000-0002-3510-9255
Golla, Heidrun https://orcid.org/0000-0002-4403-630X
,
Müller, Dirk
Hobus, Dorthe
Bonmann, Eckhard
Schwartzkopff, Franziska
Nelles, Gereon
Palmbach, Gundula
Temmes, Herbert
Franke, Isabel
Haas, Judith
Strupp, Julia
Gerbershagen, Kathrin
Becker-Peters, Laura
Burghaus, Lothar
Hellmich, Martin
Paus, Martin
Ungeheuer, Solveig
Kochs, Sophia
Stock, Stephanie
Joist, Thomas
Limmroth, Volker
-
Funding
Funding for this research was provided by:
Innovation Funds of the Federal Joint Committee (01VSF19029)
Innovation Funds of the Federal Joint Committee (01VSF19029)
Innovation Funds of the Federal Joint Committee (01VSF19029)
Innovation Funds of the Federal Joint Committee (01VSF19029)
Innovation Funds of the Federal Joint Committee (01VSF19029)
Innovation Funds of the Federal Joint Committee (01VSF19029)
Innovation Funds of the Federal Joint Committee (01VSF19029)
Innovation Funds of the Federal Joint Committee (01VSF19029)
Universitätsklinikum Köln
- License Information
-
More Information
Article History
Received: 23 November 2023
Accepted: 11 March 2024
First Online: 10 April 2024
Declarations
:
: Participants were provided with oral and written information about the trial and provided written informed consent. Ethical approval was obtained from the Ethics Committee of the University of Cologne (#20–1436). The trial is registered in the German Register for Clinical Studies (DRKS) (DRKS00022771) and is conducted under the Declaration of Helsinki.
: Not applicable.
: Clemens Warnke has received institutional support from Novartis, Alexion, Sanofi Genzyme, Janssen, Biogen, Merck and Roche. The other authors declare that they have no competing interests.
